Genomic Vision: Financial information for the 4th quarter of 2022 – 02/28/2023 at 07:00
• Revenues from the 2022 activity are up 5% at €1.48 million
• 2022 sales of products and services increase by 3% to €1.03 million
• Financial resources provide financial visibility for the next 12 months
Total revenue from the activity as of December 31, 2022 amounted to €1,480 thousand, up 5% compared to December 31, 2021, and breaks down as follows:
• the turnover for the year 2022 (€1,026K) up 3% compared to 2021, these two financial years each including the sale of a platform,
• other income, amounting to €454,000 as of December 31, 2022, corresponds to the research tax credit.
Total revenue from the activity in the 4th quarter of 2022 amounted to €258k compared to €374k in the 4th quarter of 2021, a decrease of -31% attributable to an unfavorable base effect linked to particularly robust activity in the 4th quarter of 2021 .